AKT1 and mantle cell lymphoma: Inhibition of Akt and ERK was particularly effective in both intrinsic and acquired venetoclax resistance, and therapies specifically targeting the PI3K/Akt pathway, such as TIC-10, may represent future directions for VR MCL.